StreetInsider.com News Articles

Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage

Mon, 10 Aug 2026 09:01:00 -0400

Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governance

Appointment further strengthens leadership team at a pivotal inflection point as Company positions ERNA-101 for planned IND submission in Q3 2026 and Phase 1 clinical study initiation in the Q4 2026

CAMBRIDGE, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the appointment of David Polinsky

Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage

Mon, 10 Aug 2026 09:01:00 -0400

Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governance

Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage

Mon, 10 Aug 2026 09:01:00 -0400

Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governance

Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage

Mon, 10 Aug 2026 09:01:00 -0400

Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governance

Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage

Mon, 10 Aug 2026 09:01:00 -0400

Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governance

Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage

Mon, 10 Aug 2026 09:01:00 -0400

Seasoned biotechnology founder, public company CFO and corporate strategist brings more than 25 years of leadership in oncology, capital markets, M&A and corporate governance

Form 4 Rafael Holdings, Inc. For: Jul 29 Filed by: JONAS HOWARD S

Fri, 31 Jul 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260731/26851469.html

Form 4 Rafael Holdings, Inc. For: Jul 29 Filed by: JONAS HOWARD S

Fri, 31 Jul 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260731/26851469.html

Form 8-K Rafael Holdings, Inc. For: Jul 08

Wed, 08 Jul 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260708/26748116.html

Form 8-K Rafael Holdings, Inc. For: Jul 08

Wed, 08 Jul 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260708/26748116.html

Form 4 Rafael Holdings, Inc. For: Jun 21 Filed by: Polinsky David

Tue, 23 Jun 2026 15:33:00 -0400

si-local-file:///var/storage/secattach/20260623/26679213.html

Form 4 Rafael Holdings, Inc. For: Jun 21 Filed by: Polinsky David

Tue, 23 Jun 2026 15:33:00 -0400

si-local-file:///var/storage/secattach/20260623/26679213.html

Form 4 Rafael Holdings, Inc. For: Jun 13 Filed by: JONAS HOWARD S

Tue, 16 Jun 2026 15:55:00 -0400

si-local-file:///var/storage/secattach/20260616/26653867.html

Form 4 Rafael Holdings, Inc. For: Jun 13 Filed by: JONAS HOWARD S

Tue, 16 Jun 2026 15:55:00 -0400

si-local-file:///var/storage/secattach/20260616/26653867.html

Form 10-Q Rafael Holdings, Inc. For: Apr 30

Thu, 11 Jun 2026 08:18:00 -0400

si-local-file:///var/storage/secattach/20260611/26632997.html

Form 10-Q Rafael Holdings, Inc. For: Apr 30

Thu, 11 Jun 2026 08:18:00 -0400

si-local-file:///var/storage/secattach/20260611/26632997.html

Form 8-K Rafael Holdings, Inc. For: Jun 11

Thu, 11 Jun 2026 07:55:00 -0400

si-local-file:///var/storage/secattach/20260611/26632693.html

Form 8-K Rafael Holdings, Inc. For: Jun 11

Thu, 11 Jun 2026 07:55:00 -0400

si-local-file:///var/storage/secattach/20260611/26632693.html

Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results

Thu, 11 Jun 2026 07:30:00 -0400

NEWARK, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the third quarter fiscal year 2026 ended April 30, 2026.

“Yesterday, we were pleased to announce that we reached the completion of the last patient last visit of our pivotal Phase 3 TransportNPC™ trial, and we are grateful for the patients and families, advocacy organizations, and physicians who stood at the heart of this global effort. Together, we have advanced the clinical understanding of NPC, as well as the lived experience of this devastating disease, as we

Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results

Thu, 11 Jun 2026 07:30:00 -0400

NEWARK, N.J., June 11, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the third quarter fiscal year 2026 ended April 30, 2026.

Form 8-K Rafael Holdings, Inc. For: Jun 10

Wed, 10 Jun 2026 07:49:00 -0400

si-local-file:///var/storage/secattach/20260610/26626816.html

Form 8-K Rafael Holdings, Inc. For: Jun 10

Wed, 10 Jun 2026 07:49:00 -0400

si-local-file:///var/storage/secattach/20260610/26626816.html

Rafael Holdings completes phase 3 study for rare disease treatment

Wed, 10 Jun 2026 07:30:09 -0400

Rafael Holdings Inc. (NYSE: RFL) completed the final patient visit for its pivotal Phase 3 TransportNPC study evaluating Trappsol Cyclo for treating Niemann-Pick Disease Type C, according to a company statement.

The study enrolled 94 patients across 27 sites in 13 countries over 96 weeks. An additional 10 patients participated in a single-arm sub-study focusing on newborns to 3-year-olds as part of a Pediatric Investigational Plan.

The company expects to announce topline results from the main study in the second half of 2026. Rafael Holdings plans to submit a New Drug Application to the FDA during the same timeframe following a completed

Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Wed, 10 Jun 2026 07:30:00 -0400

Topline results are expected to be announced in second half of calendar 2026

The company has had a pre-NDA meeting with the FDA and expects to submit an NDA in second half of calendar 2026

The company has received acknowledgement from the FDA that our US Expanded Access Program (EAP) can proceed

NEWARK, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL) today announced the last patient has completed the final 96-week study visit in the pivotal Phase 3 TransportNPC™ study evaluating Trappsol^® Cyclo™ for the treatment of

Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC™ Study Evaluating Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

Wed, 10 Jun 2026 07:30:00 -0400

Topline results are expected to be announced in second half of calendar 2026

The company has had a pre-NDA meeting with the FDA and expects to submit an NDA in second half of calendar 2026

The company has received acknowledgement from the FDA that our US Expanded Access Program (EAP) can proceed